RhoVac’s reports positive results in the company’s phase I/II clinical study
RhoVac AB (“RhoVac”) reported today, August 1, 2018, positive top-line results on safety and on immune activation in their phase I/II clinical trial RhoVac-001 in prostate cancer patients.In totally 22 prostate cancer patients received RV001 treatment over a period of approximately 30 weeks. The regimen was well tolerated and there were no treatment related grade 3, 4 or 5 reactions according to CTCAE (Common Terminology Criteria for Adverse Events). The primary end-point of the study was therefore achieved. No related allergic reactions to treatment and no treatment related SAEs (Serious